Supplementary Figure 5: Increase in maximal growth inhibition upon trametinib treatment in YAP1-depleted cells.
From: The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
(a) Effects of YAP1 knockdown on trametinib sensitivity in the indicated BRAF-mutant cell lines, shown as percentage of maximal growth inhibition (n = 4, +s.e.m. for all cell viability data shown). (b) Effects of YAP1 knockdown on trametinib sensitivity in the indicated RAS-mutant cell lines, shown as percentage of maximal growth inhibition (n = 4, +s.e.m. for all cell viability data shown).
